Summary: Platelet-activating factor has been implicated in a variety of disease processes including ischemic brain injury and endotoxic shock, but its effects on cerebral blood flow (CBF) and metabolism in normal brain have not been described. The effects of platelet-activating factor on global CBF (hydrogen clearance) and the global cerebral metabolic rate for oxygen (CMR02) were studied in halothane-N20 anesthetized Wi star rats. Hex adecyl-platelet-activating factor infused into the right ca rotid artery (67 pmollmin) for 60 min decreased mean ar terial pressure (MAP) from 122 ± 4 (x ± SEM) to 77 ± 6 mm Hg and CBF from 159 ± 12 to 116 ± 14 mlllOO g/min Platelet-activating factor, the alkoxyether lipid 1-0-alky 1-2-acety I-sn-glycery 1-3-phos phory lcho line, is an endogeneous and potent ether-phospho lipid with a wide spectrum of biologic effects. Nan omolar quantities of this substance cause increased microvascular permeability (Humphrey et aI., 1982; Bjork and Smedegard, 1983) ; systemic vasodilation and coronary dilation and constriction (Sybertz et aI., 1985); granulocyte activation, adherence, ag gregation, and chemotaxis (Shaw et aI., 1981); and stimulation of arachidonate-independent platelet aggregation (Namm et aI., 1982).
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A major route of platelet-activating factor pro duction is by acetylation of certain ether-phospho-(p < 0.002). In contrast, CMR02 increased from 9.7 ± 0.9 to 11.7 ± 1.1 ml/l00 g/min after 15 min (p < 0.05) . In controls rendered similarly hypotensive by blood with drawal and infused with the platelet-activating factor ve hicle, CMR02 was unchanged, whereas CBF transiently decreased then returned to baseline at 60 min. These ce rebrovascular and cerebrometabolic effects of PAF are reminiscent of and may be relevant to hypoperfusion and hypermetabolism observed after global brain ischemia and in endotoxic shock. Key Words: Cerebral blood flow -Cerebral oxygen metabolism-Platelet-activating factor.
lipids after hydrolysis by phospholipase A2 (Wykle et aI. , 1980) . Ether-lipids comprise about 4% of brain phospholipid (Clarke and Dawson, 1981) , half of which represents glycerol-ether-phospholipids with a phosphatidylcholine moiety-a potential platelet-activating factor precursor. Significant but small quantities of platelet-activating factor (10 J.1g/ brain) and a fraction of acyl platelet-activating factor analogs with similar biologic activity have been detected in normal bovine brain (Tokumura and Tsukatani, 1986; Yoshida et aI., 1986; Toku mura, et aI., 1987) .
In models of inflammation, endotoxic shock, and thrombosis, the effects of platelet-activating factor appear to mirror and augment those of other medi ators such as eicosanoids and oxygen radicals, which are thought to be important in producing re perfusion injury (Samuelsson, 1983; Denzlinger et aI., 1985; Benveniste and Chignard, 1985; Raichle, 1983) . Thus, platelet-activating factor may repre sent an important mediator of detrimental events occurring during reperfusion in the brain and other organs after ischemia and shock. Improved post-ischemic CBF and recovery of cortical somatosen sory evoked response amplitude in dogs treated with kadsurenone, a platelet-activating factor re ceptor antagonist, during ischemia and reperfusion (Kochanek et al., 1987) provide further support for this hypothesis. Similarly, both kadsurenone and BN 52021 (also a platelet-activating factor receptor antagonist) improved neurologic recovery at 6 h after 10 min of bilateral carotid artery occlusion in gerbils (Spinnewyn et aI., 1987) . However, the ef fects of platelet-activating factor on normal CBF and metabolism have not been described. This ar ticle describes the effects of platelet-activating factor-induced hypotension on CBF and CMR02 in the normal rat brain.
MATERIALS AND METHODS

Surgical preparation
Barrier-bred, laboratory-acclimated, male Wi star rats (320-400 g) had free access to food and water up to the time of study. Anesthesia was induced in plastic jars in sufflated with 5% halothane in oxygen. The trachea was then intubated with a sterile 16-gauge intracath, and the rat was mechanically ventilated with 1 % halothane in 66% NzO and 33% Oz. Pancuronium, 0.1 mg/kg/h, was used for immobilization. Two femoral arterial catheters, a femoral venous catheter, and a right common carotid ar tery catheter (PE-50) were surgically inserted, and lido caine was infiltrated in all surgical sites. Rectal tempera ture was continuously monitored and maintained at 38 ± 0.2°C with an automatic heated water blanket (Yellow Springs, Inc.).
The dorsal calvarium was exposed by a midline inci sion and the rat transferred to a Faraday cage. The head was fixed in a stereotaxic device (David Kopf, Inc.), and mechanical ventilation was continued. Mean arterial pressure (MAP) was continuously monitored on a Hon eywell (model 3260) recorder. An arterial blood sample (0.4 m!) was obtained to verify that blood gases, pH (Corning model 175 blood gas machine), and hemoglobin concentration (Hb) were within normal limits. All blood samples were replaced with an equal volume of heparin ized whole blood from donor Wistar rats.
Under x 20 magnification with an operating micro scope (Jena, Inc.) and using an air dental drill, a burr hold was made over the superior sagittal sinus, and a platinum microelectrode (50-ILm tip diameter) was advanced into the sagittal sinus. After saturation with 5-6% Hz in the inspired gas, Hz washout was effected, and CBF (mll100 g/min) was calculated by the TYz method (Young, 1980) from the clearance curves. Agar gel was used to cover the space between the burr hole and the electrode to prevent diffusion of Hz gas out of the tissue into air and to ensure temperature homeostasis. The microelectrodes were used with a chemical microsensor (Diamond Electro Tech, Inc., model 1201) at a polarizing voltage of + 250 m V with the output recorded on a Linseis recorder.
To obtain cerebral venous blood samples, a second burr hole was made over the torcular, through which a 28-gauge, short-bevel, stainless steel needle was inserted.
Thereafter, 100 IU of heparin (Upjohn) was administered to the animal i.v.
Cerebral venous and systemic arterial oxygen content were determined in O.4-ml blood samples using a Co-ox imeter (Instrument Laboratories, model 282). CMROz was calculated as the product of CBF and the arterial minus cerebral venous difference in Oz content.
Platelet-activating factor preparation
Te n nanomoles (Sigma) and 10 nCi (New England Nu clear) of synthetic I-hexadecyl-platelet-activating factor dissolved in chloroform-methanol was dried under Nz, and the platelet-activating factor was resuspended in 0.25% bovine serum albumin in saline at a concentration of 1 ILg/ml by sonicating for 10 min at room temperature. At the end of each experiment, aliquots of the solution remaining in the delivery syringe were counted on a scin tillation counter (Beckman). More than 90% of the platelet-activating factor was resuspended using this technique. These precautions were taken because platelet-activating factor tends to adhere to glassware (Jackson et aI., 1986) .
Experimental protocol
After surgical preparations, the animals were stabilized for 60 min on 0.4% halothane in NzO:Oz (2: 1) and pan curonium immobilization. Subsequently, an intracarotid infusion of bovine serum albumin (0.25%) in saline at 0.035 mllmin was begun. After 15 min, MAP, CBF, CMROz, and Hb concentrations were measured in dupli cate and averaged to yield mean baseline values. Blood gas tensions and base excess were maintained within the following extreme limits: 7.40 ± 0.05 for pH, 90 ± 15 torr for Paoz, 35 ± 5 torr for Pacoz, and 0.0 ± 2.0 mmoll L for base excess.
In 10 rats, platelet-activating factor was infused at a rate of 0.035 mllmin (67 pmol/min) into the right common carotid artery. After 15 min, all monitored variables were measured again. On the basis of Pacoz and base excess from blood samples obtained after 15 and 45 min of platelet-activating factor infusion, COz was added to the inspired gas, and NaHC03 was infused i.v. to normalize Pacoz and base excess. The platelet-activating factor de creased Pacoz and produced a metabolic acidosis. After 60 min of platelet-activating factor infusion, a complete set of variables was again obtained, and the animals were killed with i. v. saturated KCL.
In seven rats, the platelet-activating factor vehicle (0.25% bovine serum albumin in saline) was infused into the right carotid artery at 0.035 mllmin combined with graded hemorrhage to lower the MAP to a range of 70 ± 3 mm Hg as produced by platelet-activating factor. MAP was maintained at this level by further withdrawal or reinfusion of shed blood from a heparinized syringe, as needed. Variables were measured as in the platelet-acti vating factor group. Carbon dioxide and sodium bicar bonate were used to control Pacoz and base excess, re spectively.
Data analysis
Statistical comparisons within groups were made using the repeated measures analysis of variance followed by the Student t test with the Bonferroni correction and the Wilcoxon signed-rank test with correction for multiple comparisons (Glantz, 1987) . Baseline comparisons be-tween groups were made using the Student t test and the Wilcoxon rank-sum test. Differences of p < 0.05 were considered to be statistically significant.
RESULT S
Platelet-activating factor infused at 67 pmollmin decreased MAP (p < 0.002) by 43% at 15 min and 37% at 60 min (Table O . Paco2 and base excess also fell at 15 min but were corrected by 60 min with CO2 and bicarbonate administration (Table O. The increase in Hb concentration during platelet-acti vating factor administration observed by others (Doebber et al., 1985) was not statistically signifi cant in this study.
In platelet-activating factor-infused rats, CBF decreased 17% (p < 0.02) and 25% (p < 0.002) after 15 and 60 min, respectively (Fig. 1) . CMR02 in creased by more than 21% (p < 0.05) after 15 min of platelet-activating factor infusion (Fig. 2) . Although CMR02 remained elevated in seven of ten animals after 60 min, it was not significant because it de creased in three animals from 9.7 ± 0.9 to 5.3 ± 1.3 mllIOO g/min (Table I ). The three animals in which CMR02 decreased between 15 and 60 min also demonstrated the most pronounced decreases in CBF at 60 min (30%,57%, and 68%). In the other seven animals, CMR02 at I h was nearly identical to CMR02 at 15 min (1l.5 ± 1.4 mllIOO g/min; p < 0.05; Fig. 2) .
None of the controlled variables differed signifi cantly between the platelet-activating factor and controls treated at baseline (Table I ). MAP was 9.7 ± 0.9 11.7 ± l.Ie 9.6 ± 1.4
Temperature eC)
37.7 ± 0.2 37.6 ± 0.2 37.7 ± 0.2
Paco2 (torr)
36 ± I 31 ± 2" 38 ± 2
Base excess (mmoIlL) �1.5±0.7 �4.3 ± 0.5b �2.6 ± 0.4
13.1 ± 0.2 14.3 ± 0.7 13.7 ± 0.7 Group 2
MAP (mm Hg)
119 ± 5 66 ± 6" 70 ± 3" CBF (mill 00 g/min)
143 ± 22 123 ± 25b 137 ± 21 CMR02 (mllIOO g/min)
9.3 ± 1.6 10.0 ± 1.8 9.6 ± 2.1
Temperature (0C)
38.0 ± 0.2 37.9 ± 0.2 37.7 ± 0.2
Paco2 (torr)
38 ± 2 36 ± 2 37 ± 2
Base excess (mmoIlL)
�O.I ± 0.3 � 1.0 ± 0.8 � 1.6 ± 0.8
13.1 ± 0.2 11.3 ± 0.3" 9.8 ± 0.2"
All values are means ± SEM; group I, platelet-activating factor, 10 rats; group 2, hemorrhage, seven rats.
" Significantly different from baseline value at p < 0.002. b Significantly different from baseline value at p < 0.02. similar in the platelet-activating factor and control groups at the three time points. As in the platelet activating factor-infused rats, MAP decreased sig nificantly at IS min by 43% and 60 min by 41% after hemorrhage ( Table 1) . CBF fell by 14% (p < 0.02) and 4% (NS) after 15 and 60 min of hemorrhagic hypotension (Fig. 1) . No significant change in CMR02 was observed at either 15 or 60 min in con trol rats (Pig. 2). Hb decreased after 15 and 60 min of hemorrhagic hypotension ( Table 1) .
DISCUSSION
Intracarotid PAP administration produced a 37 -43% decrease in MAP similar to that observed during i. v. platelet-activating factor administration (Sanchez-Crespo et ai., 1982; Lai et ai., 1983; Doebber et ai., 1985) . A significant increase in CMR02 and a decrease in CBP occurred during platelet-activating factor-induced hypotension. Unlike the effects of platelet-activating factor and hemorrhage on CBP at 15 min, the effects of platelet-activating factor-induced hypotension on CBP at 60 min occurred despite control of Paco2 and base deficit. A 25% decrease in CBP was ob served at a level of MAP within the CBP autoregu latory range for the rat (Barry et ai., 1984) . Using an identical preparation and anesthetic, a 41% de crease in MAP produced by hemorrhagic hypoten sion did not significantly alter CBP at 60 min. The 4% decrease in CBP at 60 min in hemorrhaged an imals corroborates work by others (Pitch et al., 1975) . The baseline CBP values observed in rats from both groups are similar to those observed by others using a comparable anesthetic (Carlsson, 1976) . The decrease in CBP observed with platelet activating factor administration could be a result of direct or indirect vasoconstrictor effects of platelet activating factor on the cerebral circulation, effects of platelet-activating factor on local CBP autoregu lation, and/or result from altered systemic hemo dynamics. Picomolar bolus doses of platelet-acti vating factor have been recently shown to produce a biphasic effect on carotid blood flow in the pig (Piper et ai., 1987) . A small «8%) transient in crease in carotid blood flow was followed by a pro longed dose-dependent reduction in flow (26-64%).
The microvascular actions of platelet-activating factor vary considerably between species (Namm et aI., 1982; Lee and Snyder, 1985; Braquet et aI., 1987) . Por example, the microvasculature and blood elements in humans are quite responsive to platelet-activating factor. Many of the actions of platelet-activating factor have been shown to be mediated at least in part through the stimulation of local eicosanoid production, particularly throm boxane A2 and the leukotrienes (Voelkel et ai., 1983; Heffner et ai., 1983; Peuerstein et aI., 1984; Braquet and Vargaftig, 1986) . In the rat, it is un likely that stimulated thromboxane A2 synthesis is the major cause of vasoconstriction since rat platelets, the major source of thromboxane, are not responsive to platelet-activating factor (Namm et aI., 1982; Sanchez-Crespo et ai., 1982) . Vasocon striction may, however, be mediated by leuko trienes since rat granulocytes, a major source of leukotrienes, are markedly stimulated by platelet activating factor (Struyker-Boudier et ai., 1985) . A local effect of platelet-activating factor, eliminating or attenuating CBP autoregulation, could also ex plain the decrease in CBP observed with platelet activating factor-induced hypotension. Although fu rther studies are needed to support or refute this possibility, the detrimental role of platelet-acti vating factor proposed during postischemic reper fusion (Kochanek et aI., 1987; Spinnewyn et al., 1987) may be related to the loss of CBP autoregula tion commonly seen after ischemic insults or platelet-activating factor-induced vasoconstriction. Negative inotropic effects of platelet-activating factor on the myocardium (Sybertz et ai., 1984; Saeki et aI., 1985) and the ability of platelet-acti vating fa ctor to decrease intravascular volume and produce metabolic acidosis also may contribute to the decrease in CBP observed despite maintenance of MAP within the CBP autoregulatory range. Pactors other than simply an adequate MAP are important determinants of CBP even within the au toregulatory range; both adequate cardiac output and intravascular volume status appear to be im portant (Davis and Sundt, 1980) . CMR02 significantly increased after 15 min of platelet-activating factor administration. At 60 min, CMROz remained elevated in seven of the ten platelet-activating factor-treated animals, but de creased dramatically in three animals-the same animals in which CBP decreased 30%, 57%, and 68%. Because of the large decreases in CBP in these three animals, CMROz may have been perfu sion limited. In light of this, these three animals were eliminated from CMROz data analysis at 60 min (Pig. 2).
The unusual pattern of increased CMROz accom panied by a decrease in CBP and MAP observed during platelet-activating factor infusion occurs also with i. v. endotoxin administration (Ekstrom10dal et ai., 1982) and during the delayed phase of postischemic reperfusion (Snyder et ai., 1975; Hossman, 1982) . Endotoxin (1 mg/kg i.v.) produced a simultaneous 30% decrease in CBP, a 40% in crease in CMROz, and a 41% decrease in MAP, all occurring within 1 h of administration in dogs (Ek strom-lodal et aI., 1982) . These findings are strik ingly similar to those observed in our study during platelet-activating factor administration. As seen with endotoxin (Ekstrom-lodal et aI., 1982) , the in crease in CMROz during platelet-activating fa ctor administration may represent a secondary effect of increased plasma catecholamines with altered blood-brain barrier permeability (MacKenzie et al., 1976) . Recent studies in dogs demonstrate dramatic increases in plasma epineph rine and norepinephrine concentrations during platelet-activating factor-induced hypotension to a MAP similar to that observed in this study. How ever, the effects of platelet-activating factor on the blood-brain barrier remain undetermined. The dra matic decrease in CMR02 in the three rats with marked decreases in CBP at 60 min is similar to the conversion from the hyperdynamic to hypody namic form of endotoxic shock commonly observed clinically and experimentally (Wetzel, 1987) .
In conclusion, platelet-activating factor-induced hypotension in rats produces a significant decrease in CBP and an increase in CMR02 despite the maintenance of MAP within the CBP autoregula tory range. Although the mechanisms remain to be determined, these effects bear a striking resem blance to those observed during endotoxin adminis tration and postischemic hypoperfusion. Mecha nistic studies are needed to further characterize this effect and determine the importance of platelet-ac tivating factor in cerebral pathobiology.
